Gregory M. Weinhoff serves as Chief Business Officer of Centessa Pharmaceuticals plc (CNTA). Weinhoff has reported 10 insider filings with the SEC since 2024. The most recent filing was in June 2026.
Every role Gregory M. Weinhoff has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Centessa Pharmaceuticals plc (CNTA)1 filingUpdated Aug 31, 2026
Gregory M. Weinhoff is Chief Business Officer of Centessa Pharmaceuticals plc (CNTA). 10 SEC Form 4 filings on record going back to 2024, most recently on 24 June 2026. Most recent open-market trade: sold $720K of CNTA on 27 March 2026. Lifetime open-market sales: $3.33M.
Every recent SEC Form 4 transaction Gregory M. Weinhoff has reported, most recent first.
InsiderAlpha's records for Gregory M. Weinhoff go back to 2024: 10 primary Form 4 filings, an average of 3.3 per year. 12 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Gregory M. Weinhoff files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Gregory M. Weinhoff is a corporate insider, tracked as Chief Business Officer of Centessa Pharmaceuticals plc (CNTA). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
1 primary Form 4 filing in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases and 7 open-market sales ($3.33M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial